Category
The FDA has launched a pilot program allowing regulators to review clinical trial data as it is generated, starting with trials involving AstraZeneca and Amgen. This shift moves oversight from retrospective auditing to continuous monitoring of patient events like tumor size changes. The initiative aims to accelerate the timeline for bringing new medications to patients by catching issues sooner.
Former NIH advisor Dr. David Morens faces federal charges for allegedly using private email to conceal records related to COVID-19 research. This indictment raises questions about data transparency and compliance within government agencies during public health crises. The case subjects a prominent scientific figure to scrutiny over how sensitive research communications are managed.
South Carolina has declared its measles outbreak over after confirming 997 total cases, with the majority concentrated in Spartanburg County. This significant event underscores a major public health concern regarding localized immunization disparities across the state.
Greece and France formalized a strategic partnership focusing on defense technology and regional stability. The most significant finding is the mutual declaration of forming a "Mediterranean axis," which signals an elevated geopolitical alignment for both nations amid global shifts. This dual focus pairs enhanced international security with domestic support measures, including €500 million in aid for Greek citizens.
Artemis II astronauts urged global unity after their lunar flyby, describing Planet Earth as a fragile "lifeboat." This framing suggests the mission's narrative could influence international policy discussions toward collective vulnerability over geopolitical conflict. The flight also successfully completed an extensive distance around the Moon, validating deep-space technological capabilities.
Two children have died from measles complications during an outbreak in West Texas, with case numbers nearing 500 in the region. The fatalities occurred among unvaccinated or unconfirmed vaccination status children, highlighting immediate public health risks associated with low community immunity.
Kura Oncology secured a $30 million milestone payment for its drug Ziftomenib, but early trial data also documented serious adverse events like Differentiation Syndrome in 26% of patients. This highlights a critical tension between financial validation and clinical risk as the company moves forward with AML treatments.
S&P Global is selling its geoscience software to SLB while simultaneously launching the new AI platform, Titan. This dual action signals S&P's shift away from maintaining legacy infrastructure toward focusing on proprietary data intelligence. Readers should note this suggests a potential industry split between specialized data providers and integrated software firms in the energy sector.
